Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Diagnosis

18F-fluorodeoxglucose (FDG) positron emission tomography (PET) to measure response and prediction of outcome to relapsed/refractory mantle cell lymphoma (MCL) therapy with bendamustine-rituximab (BR)

D. Lamonica, D. Graf, K. Attwood, M. Munteanu and M. Czuczman
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1351;
D. Lamonica
3Roswell Park Cancer Institute, Buffalo, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Graf
2Nuclear Med Residency (Now at UTMB), U at Buffalo, Buffalo, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Attwood
3Roswell Park Cancer Institute, Buffalo, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Munteanu
1Teva BPP R&D, Inc., Fraser, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Czuczman
3Roswell Park Cancer Institute, Buffalo, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 56 no. supplement 3 1351

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 15, 2015.

Copyright & Usage 

Author Information

  1. D. Lamonica3,
  2. D. Graf2,
  3. K. Attwood3,
  4. M. Munteanu1 and
  5. M. Czuczman3
  1. 1Teva BPP R&D, Inc., Fraser, PA
  2. 2Nuclear Med Residency (Now at UTMB), U at Buffalo, Buffalo, NY
  3. 3Roswell Park Cancer Institute, Buffalo, NY

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2015 to April 2025

AbstractFullPdf
May 20151000
Jun 2015400
Jul 2015500
Aug 2015600
Sep 2015800
Oct 2015200
Nov 2015100
Dec 20151400
Jan 20161200
Feb 2016800
Mar 2016200
Apr 2016200
May 20161000
Jun 2016300
Jul 20161100
Aug 2016400
Sep 2016800
Oct 2016700
Nov 20161100
Dec 2016500
Jan 20171400
Feb 2017100
Mar 2017900
Apr 2017600
May 2017700
Jun 2017300
Jul 2017500
Aug 2017200
Sep 2017300
Oct 2017400
Nov 2017400
Dec 2017300
Jan 2018200
Feb 2018200
Mar 2018300
Apr 2018100
May 2018500
Jun 2018100
Aug 2018100
Sep 2018200
Nov 2018100
Dec 2018100
Jan 2019300
Feb 2019100
Mar 2019500
Apr 2019100
May 2019200
Jun 2019200
Jul 2019300
Sep 2019100
Oct 2019300
Nov 2019100
Dec 2019300
Jan 2020100
Feb 2020300
Mar 2020500
Apr 2020200
May 2020100
Sep 2020100
Oct 2020100
Dec 2020400
Jan 2021600
Feb 2021900
Mar 20212000
Apr 20211400
May 2021800
Jun 2021500
Jul 2021400
Aug 2021400
Sep 2021400
Oct 2021100
Nov 2021200
Dec 2021200
Jan 2022200
Feb 2022300
Mar 2022500
Apr 2022300
May 2022200
Jun 2022200
Aug 2022200
Oct 2022100
Feb 2023100
Mar 2023300
Apr 2023100
May 2023500
Jun 2023100
Jul 2023400
Aug 2023200
Sep 2023400
Oct 2023400
Nov 2023200
Dec 2023100
Jan 2024500
Feb 2024100
Mar 2024700
Apr 2024200
May 2024600
Jun 2024200
Jul 2024100
Aug 20241500
Sep 2024700
Nov 2024500
Dec 2024600
Jan 2025100
Feb 2025400
Mar 2025400
Apr 2025400
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F-fluorodeoxglucose (FDG) positron emission tomography (PET) to measure response and prediction of outcome to relapsed/refractory mantle cell lymphoma (MCL) therapy with bendamustine-rituximab (BR)
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
18F-fluorodeoxglucose (FDG) positron emission tomography (PET) to measure response and prediction of outcome to relapsed/refractory mantle cell lymphoma (MCL) therapy with bendamustine-rituximab (BR)
D. Lamonica, D. Graf, K. Attwood, M. Munteanu, M. Czuczman
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1351;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F-fluorodeoxglucose (FDG) positron emission tomography (PET) to measure response and prediction of outcome to relapsed/refractory mantle cell lymphoma (MCL) therapy with bendamustine-rituximab (BR)
D. Lamonica, D. Graf, K. Attwood, M. Munteanu, M. Czuczman
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1351;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Diagnosis

  • Diagnosis value of trimoality PET/CT-MR in digestive tract disease
  • Activity in pulmonary nodules on standard iterative compared to time of flight reconstructed 18F-FDG PET/CT.
  • 11C-acetate PET/CT for prediction of negative lymph node involvement of prostate cancer before prostatectomy
Show more Oncology: Clinical Diagnosis

MTA I: Leukemia/Lymphoma/Myeloma Posters

  • Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphoma.
  • Role of initial, interim, and post-treatment F-18 FDG PET/CT in prognostication of clinically diagnosed extranodal lymphoma
  • FDG avidity of mediastinum and liver on sequential PET/CT scans in NKT cell lymphoma nasal type
Show more MTA I: Leukemia/Lymphoma/Myeloma Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire